New Directions in Diagnostics Innovation

Biomarker discovery and renewed attention on the regulatory front is ushering in a new era for diagnostic tools. Artificial intelligence continues to modernize the way we diagnose disease, allowing for increased speed and accuracy. Among oncology, we are seeing approaches to biopsies evolving and global reimbursement of NGS improving and allowing for more efficient testing of multiple biomarkers. As companies pursue drug development and commercialization, leadership teams are realizing that any form of success will need to incorporate diagnostic tools as companions to drug therapy. This panel will review the diagnostics landscape, where we are seeing the most innovation and what strategies are being deployed to drive drug development and patient care.